Literature DB >> 10953330

Chemo-immunotherapy of ovarian cancer in a murine tumour model.

A H Klimp1, E G De Vries, G L Scherphof, T Daemen.   

Abstract

BACKGROUND: As a majority of ovarian cancer patients will ultimately develop recurrent disease, there is an urgent need for alternative or additional approaches in the treatment of this cancer.
MATERIALS AND METHODS: The antitumour effect of i.p. administered cisplatin, liposomal muramyltripeptide phosphatidylethanulamine (L-MTP-PE) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were investigated using an i.p. growing murine ovarian tumour. Tumour growth was followed by measuring weight and survival of the mice.
RESULTS: An i.p. injection of L-MTP-PE in non-tumour bearing mice resulted in an approximately 10-fold increase in the number of peritoneal cells, which were highly cytotoxic. Nonetheless, treatment of mice inoculated with MOT cells with cisplatin, L-MTP-PE and GM-CSF using different treatment schedules did not result in inhibited tumour growth when compared to treatment with cisplatin alone.
CONCLUSION: Although L-MTP-PE showed an enormous increase in peritoneal cells with high tumour cytotoxic capacity, the immunotherapeutic treatment with GM-CSF and L-MTP-PE, aimed at the recruitment and activation of the peritoneal cell population, failed to result in a significant prolongation of survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953330

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.

Authors:  Erik E Johnson; Ilia N Buhtoiarov; Mark J Baldeshwiler; Mildred A R Felder; Nico Van Rooijen; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2011-01       Impact factor: 4.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.